JAMA

is rapidly entering health care, but adding more technology does not necessarily improve care and may add to alarm fatigue in already crowded clinical environments.

🎙️ In this episode of JAMA+ AI Conversations, JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, spoke with Bon Ku, MD, MPP, program manager at the Advanced Research Projects Agency for Health about how simulation-based testing may help assess artificial intelligence systems before they are used in real-world care.

How ARPA-H Is Rethinking Innovation in Health Care JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, and Bon Ku, MD, MPP, program manager at the Advanced Research Projects Agency for Health (ARPA-H), discuss what it will take to design AI systems that meaningfully improve health for the JAMA+ AI Conversations podcast.

📝 : is a cancer that arises from B lymphocytes, a type of white blood cell.

This JAMA Patient Page describes risk factors, common symptoms such as painless lymph node swelling and B symptoms, and how classic Hodgkin lymphoma is diagnosed and staged.

https://ja.ma/4hcL1Rj

Among older adults in the US, use of prescription medications and dietary supplements remained common between 2015-2016 and 2021-2023, while polypharmacy involving both categories increased.

More than 1 in 5 older adults in 2021-2023 were potentially at risk of a major drug-drug interaction, a finding relevant to medication safety, deprescribing, and adverse drug event prevention.

https://ja.ma/3TPhBj5

💬 Editorial by JAMA and JAMA Network senior editorial staff: can be an effective format for focused studies that address timely clinical, policy, and public health questions. The format is particularly well suited to straightforward analyses and concise interpretation, while maintaining the same rigorous peer and editorial review as full-length Original Investigations.

https://ja.ma/4AD2jPd

💬 Viewpoint by James A. Feinstein, MD, MPH, Amy Huebschmann, MD, MSCS, Russell Glasgow, PhD, and Lilia Cervantes, MD, MSC: The National Institutes of Health policy change barring K award funds from supporting pilot may weaken a key mentored pathway for - to develop independence in .

Leading a pilot clinical trial is distinct from participating in a mentor’s trial because it builds operational, regulatory, and decision-making skills needed for later principal investigator roles.

https://ja.ma/4xMKuuq

💬 Perspective by George Vivek Koshy, DO, MPH, Ari B. Friedman, MD, PhD, Hao Yu, PhD, and Anish K. Agarwal, MD, MPH, MS:

emergency were created to preserve emergency care in rural communities by allowing hospitals to forgo inpatient acute care beds in exchange for enhanced Medicare outpatient payments and a fixed monthly facility payment.

Uptake has remained limited, in part because current policy excludes key revenue sources such as swing beds and 340B drug pricing, which may reduce the financial viability of conversion.

https://ja.ma/4yKMQuo

💡 JAMA Insights: is a legal protection recognized in international and US law for people with a well-founded fear of persecution based on 1 of 5 protected grounds.

This JAMA Insights explains how medicolegal evaluations, guided by the Istanbul Protocol and submitted as signed affidavits, can strengthen clinical documentation used by adjudicators in asylum cases and may support more consistent review of claims.

https://ja.ma/3VadrTk

: affects millions of people worldwide and remains poorly understood, poorly defined, and poorly treated.

🎙️ In this episode of , JAMA Senior Editor Derek C. Angus, MD, MPH, spoke with E. Wesley Ely, MD, MPH, about how long COVID came to be recognized as distinct from post-intensive care syndrome and why a broader working definition from the National Academies of Sciences, Engineering, and Medicine may help improve clinical recognition and research consistency.

Long COVID: The Problem Society Wants to Forget Long COVID, including the difficulty in defining it and caring for patients experiencing it, is discussed by JAMA Senior Editor Derek C. Angus, MD, MPH, and E. Wesley Ely, MD, MPH, professor of medicine at Vanderbilt University, for this episode of the Healthy Dialogue podcast.

In , the urinary albumin creatinine ratio and urinary protein creatinine ratio provided clinically similar risk prediction for kidney and cardiovascular outcomes in a large cohort with established disease.

Although the urinary albumin-creatinine ratio was more strongly associated with kidney failure statistically, it did not provide meaningfully better discrimination, reclassification, or decision support than the urinary protein-creatinine ratio.

https://ja.ma/4rr3IUP

📊 Research Summary: For late-window due to , adding intravenous tenecteplase before thrombectomy did not improve functional outcomes, and safety outcomes were similar between groups.

https://ja.ma/46GVuyc